gefitinib
ASCO Report: Gefitinib Beats Chemo After Surgery in NSCLC
Results from a Phase III trial demonstrate that the EGFR-targeted therapy gefitinib is more effective than ...
MAY 22, 2017
LUX-Lung 7 Update: Trend for OS Benefit for Afatinib
Copenhagen, Denmark—Updated results from the Phase IIb LUX-Lung 7 trial of afatinib versus gefitinib were ...
FEBRUARY 3, 2017
EGFR Mutation Subtypes May Affect Survival In NSCLC Patients
The type of mutation in the EGFR has a strong effect on outcome in patients with NSCLC receiving first-line ...
JANUARY 25, 2017
Load more